• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intarcia, Calibr collaborate to develop peptide therapeutic for Medici pump

January 9, 2017 By Sarah Faulkner

Intarcia, Calibr collaborate to develop peptide therapeutic for Medici pumpIntarcia Therapeutics and the California Institute for Biomedical Research said today that the 2 groups will collaborate to develop a peptide therapeutic for patients with type II diabetes and obesity. The drug will be derived from Calibr’s stapled-peptide technology platform, combined with Intarcia’s late stage investigational GLP-1 therapy and delivered using the match-sized Medici osmotic pump.

According to the deal, Calibr will receive an upfront grant of Intarcia equity and additional shares vesting over key development milestones. Calibr could also earn undisclosed cash payments after reaching predetermined regulatory and sales milestones, as well as tiered royalties on product sales.

“We are committed to disruptive innovation leveraging our proprietary Medici Drug Delivery System and we now have several combination products in our pipeline that we believe we can uniquely optimize and deliver in a once- or twice-yearly mini-pump,” Intarcia Therapeutics chairman, president & CEO Kurt Graves said in prepared remarks. ” We’re excited to advance a combination program with Calibr that is targeting significant advances for patients suffering from type 2 diabetes and obesity.”

“This collaboration is another example of Calibr’s drive to work with innovative partners who are committed to making a difference in human health,” Calibr’s chief operating officer Matt Tremblay added. “We look forward to working with Intarcia to leverage our peptide technology platform to create transformative new medicines.”

The company said in December that it raised $206m in a Series EE round and landed a deal with the Bill & Melinda Gates Foundation to fight HIV. Cambridge, Mass.-based Intarcia said the investment from the Gates involves an initial $50 million contribution for the HIV project and an additional $90 million in non-dilutive grants associated with milestones for the program.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Research & Development, Wall Street Beat Tagged With: California Institute for Biomedical Research, Intarcia Therapeutics

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS